Abstract

Transformation of normal cells into cancer cells almost invariably goes along with increased levels of DNA damage. An important source of DNA damage is the enhanced activity of growth-promoting transcription factors, such as MYC. Oncogenic activation of these transcription factors aberrantly stimulates DNA replication, which leads to replication stress and ensuing DNA breaks. Cells respond to this type of stress by activation of the DNA damage response (DDR). The DDR is a complex signaling network, displaying multiple levels of cross-talk and feed-back control. Its kinase-driven signaling axes ensure rapid responses to DNA lesions, which is complemented by its transcriptional axis that warrants maintained signaling. Ultimately, activation of the DDR prevents further proliferation and thus provides time to repair genotoxic lesions, and in case of excessive levels of DNA damage promotes permanent cell cycle exit (senescence) or programmed cell death (apoptosis). Activation of the DDR thus prevents the outgrowth of incipient tumor cells, early during tumorigenesis.

Highlights

  • Transformation of normal cells into cancer cells almost invariably goes along with increased levels of DNA damage

  • Oncogenic activation of these transcription factors aberrantly stimulates DNA replication, which leads to replication stress and ensuing DNA breaks. Cells respond to this type of stress by activation of the DNA damage response (DDR)

  • Loss of specific DDR components leaves tumor cells more dependent on their remaining DDR components, especially under conditions of elevated levels of DNA damage induced by chemo/radiotherapy

Read more

Summary

Introduction

Transformation of normal cells into cancer cells almost invariably goes along with increased levels of DNA damage. Editorial: Cancer-Associated Defects in the DNA Damage Response: Drivers for Malignant Transformation and Potential Therapeutic Targets Cancer-Associated Defects in the DNA Damage Response: Drivers for Malignant Transformation and Potential Therapeutic Targets

Results
Conclusion

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call

Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.